While heterozygous carriers do not suffer from ataxia telangiectasia syndrome, they have an increased risk of developing heart disease, diabetes, and cancers, specifically breast cancer, compared to individuals with normal ATM expression levels [2], [3]. This evidence concerns the gene ATM and ataxia telangiectasia.